Document is current
Any future updates will be listed below
-
Authors
Dennis, Brittany B.
Thabane, Lehana
Heels-Ansdell, Diane
Dionne, Joanna C.
Binnie, Alexandra
Tsang, Jennifer
Guyatt, Gordon
Ahmed, Aijaz
Lauzier, François
Deane, Adam
Arabi, Yaseen
Marshall, John
Zytaruk, Nicole
Saunders, Lois
Finfer, Simon
Myburgh, John
Muscedere, John
English, Shane
Ostermann, Marlies
Hardie, Miranda
Knowles, Serena
Cook, Deborah https://orcid.org/0000-0002-4087-543X
,
-
Funding
Funding for this research was provided by:
Physicians' Services Incorporated Foundation (R22-33)
Canadian Institutes of Health Research (201610PJT-378226-PJT-CEBA-18373, 202207CL3-492565-CTP-CEBA-19215)
Hamilton Academy of Health Sciences Organization (HAH-22-009)
- License Information
-
More Information
Article History
Received: 3 July 2023
Accepted: 16 August 2023
First Online: 30 August 2023
Declarations
:
: The main REVISE trial was approved in participating hospitals by all relevant ethics committees and regulatory authorities prior to starting enrollment. The Hamilton Integrated Research Ethics Board (HiREB) under Clinical Trials Ontario (CTO Study ID 1360) is the main REB of record, which also approved this substudy. Ethics review for the additional COVID-19-specific data collection was undertaken as needed to comply with local regulations in each participating center.
: Not applicable for this protocol.
: All authors are involved in the REVISE Trial in some capacity. Otherwise, the authors declare that they have no competing interests.
